Obi Pharma Inc.

Yih-Huang Hsieh

Cheng-Der Tony Yu

I-Ju Chen

Yu-Hsin Lin

Yu-Chen Lin

Wei Lee

Cheng-Chi Wang

Shu-Yi Lin

Wei-Han Lee

Nan-Hsuan Wang

Yu Chen Lin

Peiwen Yu

Yin-Cheng Hsieh

Chung Hao Chang

Nan Hsuan Wang

Ming-Tain Lai

Chin-Sheng Chao

Chung-Hao Chang

Kuo-Pao Lai

Cheng Der Tony Yu

Cheng Der Yu

Wei Han Lee

The present disclosure is related to the six isomer structures (OBI-821-1990-V1A, OBI-821-1990-V1B, OBI-821-1990-V2A, OBI-821-1990-V2B, OBI-821-1858-A, and OBI-821-1858-B) of isolated OBI-821 adjuvant and the method for evaluating the quality thereof. The method of the present disclosure adopts hydrophilic interaction liquid chromatography (HILIC) and reverse phase high performance liquid chromatography (RP-HPLC) either alone or in tandem and is able to separate the isomers of OBI-821 adjuvant in the consequent chromatography. Accordingly, the quality of OBI-821 adjuvant can be further evaluated.

Saponin adjuvant and evaluation method thereof

A new process to synthesis of compound OBI-3424 R-form and S-form products is provided. The 'R-form' compound OBI-3423 was first synthesized with 48% overall yield from compound OBI-3424-5 by installation of the labile phosphate motif at later stage. The stereo chemistry is established by 5 steps chemo-enzyme combination synthesis to afford 99% optical purity. After then, the 'S-form' compound OBI-3424 is prepared with improving overall yield of 54% from compound OBI-3424-5. The stereo chemistry is established by 4 steps combination of chemo-enzyme synthesis with excellent optical purity of 99%.

Methods of making high enantioselective secondary alcohols

The present invention provides vaccines comprising carbohydrate antigen conjugated to a diphtheria toxin (DT) as a carrier protein, wherein the ratio of the number of carbohydrate antigen molecule to the carrier protein molecule is higher than 5:1. Also disclosed herein is a novel saponin adjuvant and methods to inhibit cancer cells, by administering an effective amount of the vaccine disclose herein.

Vaccines with higher carbohydrate antigen density and novel saponin adjuvant

The present disclosure encompasses immunogenic/therapeutic compositions including Globo series antigens (SSEA-4, Globo H or SSEA-3) glycoconjugates and therapeutic adjuvants (OBI-821 or OBI-834) as well as methods of making and using the same to treat proliferative diseases such as cancer. The therapeutic conjugates include an antigen linked to a carrier. In particular, the therapeutic conjugates include a SSEA-4, Globo H or SSEA-3 moiety and a KLH moiety subunit linked via a linker. The therapeutic compositions are in part envisaged to act as cancer vaccines (single valent, bi-valent or tri-valent vaccines) for boosting the body's natural ability to protect itself, through the immune system from dangers posed by damaged or abnormal cells such as cancer cells. Exemplary immune response can be characterized by reduction of the severity of disease, including but not limited to, prevention of disease, delay in onset of disease, decreased severity of symptoms, decreased morbidity and delayed mortality.

Immunogenic/therapeutic glycan compositions and uses thereof

Growing community of inventors

Taipei, Taiwan

Yih-Huang Hsieh